0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
See our latest analysis for Vertex Pharmaceuticals. Those CASGEVY and kidney disease updates are landing against a strong backdrop, with the share price at $460.31 after a roughly 21 percent 3 month share price return and a near 99 percent 5 year total shareholder return. This suggests momentum is still building rather than fading. If this kind of pipeline driven story appeals to you, it could be worth exploring other healthcare names using our healthcare stocks to spot similar opportunities. With shares already near analyst targets and long term returns approaching 100 percent, investors face a tougher call: is Vertex still trading below its intrinsic potential, or is the market already pricing in the next growth wave? With Vertex closing at $460.31 versus a narrative fair value near $485, the current setup implies modest upside if the long term thesis delivers. Commercial success and broad payer coverage for recent launches, particularly JOURNAVX and CASGEVY, are setting [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
See our latest analysis for Vertex Pharmaceuticals. Those CASGEVY and kidney disease updates are landing against a strong backdrop, with the share price at $460.31 after a roughly 21 percent 3 month share price return and a near 99 percent 5 year total shareholder return. This suggests momentum is still building rather than fading. If this kind of pipeline driven story appeals to you, it could be worth exploring other healthcare names using our healthcare stocks to spot similar opportunities. With shares already near analyst targets and long term returns approaching 100 percent, investors face a tougher call: is Vertex still trading below its intrinsic potential, or is the market already pricing in the next growth wave? With Vertex closing at $460.31 versus a narrative fair value near $485, the current setup implies modest upside if the long term thesis delivers. Commercial success and broad payer coverage for recent launches, particularly JOURNAVX and CASGEVY, are setting [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS